Bristol-Myers beats by $0.21, beats on revs; raises low end of FY15 EPS, just below estimates
Reports Q1 (Mar) earnings of $0.71 per share, $0.21 better than the Capital IQ Consensus Estimate of $0.50; revenues rose 6.0% year/year to $4.04 bln vs the $3.8 bln consensus.
- Excluding the divested Diabetes Alliance, global revenues increased 10% or 17% adjusted for foreign exchange impact. U.S. revenues increased 16% to $2.0 billion in the quarter compared to the same period a year ago. International revenues decreased 2% to $2.0 billion.